USPTO Examiner WANG RUIXUE - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18751599BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONSJune 2024December 2024Allow610YesNo
18654901COXSACKIEVIRUS A6 STRAIN CVA6-KM-J33 AND USE THEREOFMay 2024September 2024Allow410NoNo
18620192Nant COVID Vaccine Cross ReactivityMarch 2024August 2024Allow410YesNo
18417613BROADLY SARS-CoV-2 NEUTRALIZING MONOCLONAL ANTIBODIES AND USES THEREOFJanuary 2024December 2024Allow1120NoNo
18391325ANTIBODIES FOR SARS-COV-2 AND USES THEREOFDecember 2023March 2025Abandon1410NoNo
18368338CELL HYBRIDS AS VIRUS PACKAGING CELLS FOR HIGH EFFICIENCY PRODUCTION OF GENE THERAPY VECTORS AND VIRAL VACCINESSeptember 2023October 2024Allow1421YesNo
18463731NOVEL BACTERIOPHAGE AND THERAPEUTIC AGENT FOR BACTERIAL ENDOPHTHALMITISSeptember 2023December 2024Allow1510NoNo
18035884RECOMBINANT COVID-19 VACCINE COMPOSITION COMPRISING LIPOPEPTIDE AND POLY (I:C) ADJUVANT, AND USE THEREOFMay 2023May 2025Abandon2430YesNo
18055808CONJUGATE POLYPEPTIDES AND VACCINES FOR INDUCING IMMUNE RESPONSESNovember 2022May 2025Allow3031YesNo
17918420TEST DEVICE, TEST KIT, AND TEST METHODOctober 2022January 2025Allow2750YesNo
17809742METHODS AND COMPOSITIONS FOR USE AS A PRE-TREATMENT FOR HIV THERAPIESJune 2022March 2025Abandon3211NoNo
17613322NOVEL ANTI-HEPATITIS B VIRUS ANTIBODY AND USES THEREOFNovember 2021June 2025Allow4310NoNo
17602428METHOD FOR PRODUCING CARDIOMYOCYTEOctober 2021April 2025Abandon4210NoNo
17463429IMMUNOGENIC COMPOSITIONS AND USE THEREOFAugust 2021May 2025Allow4431YesNo
17402014SALMONELLA VACCINE FOR THE TREATMENT OF CORONAVIRUSAugust 2021June 2025Abandon4631NoNo
17422575PRIMER SETS, BIOMARKERS, KIT AND APPLICATIONS THEREOFJuly 2021June 2025Allow4720YesNo
17370337RNA REPLICON VACCINES AGAINST HBVJuly 2021February 2025Abandon4301NoNo
17415412EBOLA VIRUS GLYCOPROTEIN-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOFJune 2021February 2025Abandon4410NoNo
17413902METHOD FOR IDENTIFICATION OF VIRUSES AND DIAGNOSTIC KIT USING THE SAMEJune 2021April 2025Allow4620YesNo
17311046COMPOSITION COMPRISING NC886 FOR IMPROVING ONCOLYTIC VIRUS ACTIVITY OR PRODUCTIONJune 2021April 2025Allow4730NoNo
17309425METHOD OF REDUCING NEURONAL MICROTUBULE BINDING PROTEIN TAU (TAU) LEVELSMay 2021October 2024Allow4111NoNo
17295770NOVEL ANTI-ZIKA VIRUS ANTIBODIES AND USES THEREOFMay 2021December 2024Abandon4311YesNo
17294907Dosing Regimen for Treating Influenza Virus DiseasesMay 2021July 2024Allow3810NoNo
17313947METHOD OF DEVELOPING VACCINESMay 2021June 2025Abandon4931NoNo
17291210PURIFICATION METHOD FOR VACCINE VIRUS USING AFFINITY CHROMATOGRAPHYMay 2021May 2025Abandon4930NoNo
17287730ADENO-ASSOCIATED VIRAL CHIMERIC TDP-43 PROTEINSApril 2021September 2024Allow4111YesNo
17275310Anti-HIV Antibody 10-1074 VariantsMarch 2021May 2025Allow5022YesNo
17266499METHODS FOR IMPROVED POXVIRUS YIELDSFebruary 2021April 2025Allow5130NoNo
17260930METHODS FOR TREATMENT OF CANCER USING CHIKUNGUNYA-VSV CHIMERIC VIRUSJanuary 2021December 2024Allow4720YesNo
17258898AAV VP1U CHIMERASJanuary 2021June 2025Abandon5330NoNo
17258152METHODS FOR THE RAPID AMPLIFICATION OF HEPATITIS B VIRUS NUCLEIC ACIDJanuary 2021September 2024Allow4430NoNo
17055966SYSTEMS AND METHODS FOR LIGATIONNovember 2020October 2024Abandon4720YesNo
17054338Recombinant Herpes Simplex Virus for Cancer ImmunotherapyNovember 2020April 2025Allow5330NoNo
17047843Method for Adenovirus PurificationOctober 2020July 2024Allow4530NoNo
17046701VIRAL VECTORS AND PACKAGING CELL LINESOctober 2020October 2024Allow4811NoNo
16977124RETINAL PROTECTIVE FACTOR 2 (RPF2) PROTEIN DELIVERED BY ADENO-ASSOCIATED VIRUS EXPRESSIONSeptember 2020September 2024Allow4811NoNo
16968132Bacteriophage for treatment and prevention of E. coli and B. fragilis infectionsAugust 2020December 2024Allow5230YesNo
16959658BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTIONSJuly 2020July 2024Allow4931YesNo
16762569EXOSOMES AS A VECTOR FOR GENE DELIVERY IN RESISTANCE TO NEUTRALIZING ANTIBODY AND METHODS OF THEIR MANUFACTUREMay 2020November 2024Abandon5520NoNo
16644411DELIVERY OF A GENE-EDITING SYSTEM WITH A SINGLE RETROVIRAL PARTICLE AND METHODS OF GENERATION AND USEMarch 2020March 2025Allow6031YesNo
16639639METHOD FOR GRADUAL CONSTRUCTION OF REASSORTANT INFLUENZA VIRUSFebruary 2020January 2025Abandon5941YesNo
16622180ZIKA VIRUS STRAINS FOR TREATMENT OF GLIOMADecember 2019December 2024Allow6022YesNo
16475319NON-INVASIVE METHOD AND KIT FOR CAPTURING AND ISOLATING FETAL CELLS FROM MOTHERJuly 2019July 2024Allow6011NoNo
16321634BACULOVIRUS EXPRESSION SYSTEMJanuary 2019April 2025Allow6041NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner WANG, RUIXUE - Prosecution Strategy Guide

Executive Summary

Examiner WANG, RUIXUE works in Art Unit 1671 and has examined 40 patent applications in our dataset. With an allowance rate of 65.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner WANG, RUIXUE's allowance rate of 65.0% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WANG, RUIXUE receive 2.17 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WANG, RUIXUE is 47 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +19.9% benefit to allowance rate for applications examined by WANG, RUIXUE. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 31.8% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Petition Practice

When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.